Entera Bio Stock Skyrockets On Positive EB613 Biomarker Analysis Data In Osteoporosis Study

Entera Bio Ltd (NASDAQ: ENTX) is soaring in the premarket in reaction to positive topline data from the Phase 2 trial of EB613 in postmenopausal female subjects with osteoporosis (low bone mineral density).

  • Three-month bone biomarker data analysis showed a significant increase in the P1NP biomarker in the 2.5 mg dose group after three months of treatment compared to placebo.
  • P1NP is a biomarker that indicates the rate of new bone formation and the change at three-months (primary endpoint in this Phase 2 trial.
  • On the secondary endpoints, a significant increase in Osteocalcin (a biomarker for bone formation) was also observed in the EB613 2.5 mg group after three months.
  • A significant decrease in CTX (indicative of bone mass) was observed in line with a potential anabolic effect after three months of treatment.
  • All the effects taken together indicate a potentially positive impact on bone mineral density and a reduced risk of fractures, which is the goal of anabolic osteoporosis treatment.
  • EB613 was generally well tolerated through three months of treatment.
  • The interim analysis of the three-month data from the first 50% (n=80) of subjects randomized demonstrated a significant increase in P1NP after one month of treatment at the 1.5 mg dose compared to placebo.
  • EB613 is an orally delivered human parathyroid hormone (1-34), or PTH, drug candidate positioned as the bone-building (anabolic) treatment for osteoporosis patients.
  • Entera Bio completed enrollment of a 6-month Phase 2 study evaluating multiple doses of oral EB613 (and placebo) on BMD of the spine and proximal femur (hip). Topline efficacy and safety results anticipated in the second quarter of 2021.
  • Price Action: ENTX shares jumped 179.4% at $4.49 in premarket trading on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralosteoporosisPhase 2 Trialpostmenopausal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!